Scios Natrecor
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amendment to the nesiritide NDA is expected to be filed by year's end, according to the firm. In January 1999, FDA's Cardio-Renal Drugs Advisory Committee recommended Natrecor for approval in treating chronic decompensated congestive heart failure, but FDA found the agent "not approvable" in April 1999, saying that further study was needed to "define the consequences of the pharmacodynamic profile." Enrollment has now been completed for the final Phase III, pivotal trial. The 490-patient study, known as the Vasodilation in the Management of Acute Congestive heart failure (VMAC) trial, was designed to "further evaluate the efficacy and safety of Natrecor in acutely ill patients with shortness of breath (dyspnea) at rest due to decompensated CHF," Scios said. An initial analysis of the study is expected to be released in the fal
You may also be interested in...
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.